Horizon Investments LLC Purchases 2,361 Shares of Johnson & Johnson (NYSE:JNJ)

Horizon Investments LLC boosted its stake in Johnson & Johnson (NYSE:JNJ) by 10.1% during the 4th quarter, Holdings Channel reports. The firm owned 25,627 shares of the company’s stock after buying an additional 2,361 shares during the quarter. Horizon Investments LLC’s holdings in Johnson & Johnson were worth $3,706,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of the stock. Knuff & Co LLC lifted its stake in Johnson & Johnson by 0.7% in the 3rd quarter. Knuff & Co LLC now owns 9,466 shares of the company’s stock worth $1,534,000 after purchasing an additional 64 shares in the last quarter. Vertex Planning Partners LLC lifted its stake in Johnson & Johnson by 1.3% in the 3rd quarter. Vertex Planning Partners LLC now owns 5,211 shares of the company’s stock worth $844,000 after purchasing an additional 65 shares in the last quarter. Werba Rubin Papier Wealth Management lifted its stake in Johnson & Johnson by 3.3% in the 4th quarter. Werba Rubin Papier Wealth Management now owns 2,080 shares of the company’s stock worth $301,000 after purchasing an additional 66 shares in the last quarter. Denali Advisors LLC lifted its stake in Johnson & Johnson by 1.3% in the 4th quarter. Denali Advisors LLC now owns 5,128 shares of the company’s stock worth $742,000 after purchasing an additional 67 shares in the last quarter. Finally, Sage Mountain Advisors LLC lifted its stake in Johnson & Johnson by 0.5% in the 4th quarter. Sage Mountain Advisors LLC now owns 14,564 shares of the company’s stock worth $2,106,000 after purchasing an additional 67 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Price Performance

Shares of JNJ stock opened at $164.24 on Wednesday. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86. The company has a market capitalization of $395.80 billion, a P/E ratio of 24.70, a P/E/G ratio of 2.56 and a beta of 0.47. The company’s 50-day simple moving average is $155.73 and its two-hundred day simple moving average is $156.25. Johnson & Johnson has a one year low of $140.68 and a one year high of $169.99.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, topping analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The business had revenue of $22.52 billion for the quarter, compared to the consensus estimate of $22.44 billion. During the same period in the prior year, the firm earned $2.29 EPS. The company’s revenue for the quarter was up 5.3% compared to the same quarter last year. As a group, equities analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th were paid a dividend of $1.24 per share. The ex-dividend date of this dividend was Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.02%. Johnson & Johnson’s dividend payout ratio is presently 74.59%.

Insider Activity

In other news, VP Robert J. Decker sold 6,999 shares of the stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the transaction, the vice president now directly owns 21,001 shares in the company, valued at approximately $3,483,645.88. This trade represents a 25.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Timothy Schmid sold 403 shares of the stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total transaction of $62,928.45. Following the transaction, the executive vice president now owns 15,098 shares in the company, valued at approximately $2,357,552.70. This represents a 2.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.16% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently issued reports on JNJ. Morgan Stanley decreased their target price on shares of Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating on the stock in a research report on Thursday, January 23rd. Barclays upped their target price on shares of Johnson & Johnson from $159.00 to $166.00 and gave the company an “equal weight” rating in a research report on Tuesday, January 28th. Guggenheim restated a “neutral” rating on shares of Johnson & Johnson in a research report on Monday, March 10th. Royal Bank of Canada restated an “outperform” rating and set a $181.00 target price on shares of Johnson & Johnson in a research report on Wednesday, February 19th. Finally, Bank of America upped their target price on shares of Johnson & Johnson from $159.00 to $171.00 and gave the company a “neutral” rating in a research report on Wednesday, March 5th. Nine equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and an average price target of $171.33.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.